


Connect Biopharma Email Formats
Biotechnology Research • 3580 Carmel Mountain Road, Suite 200, United States • 21-50 Employees
Connect Biopharma Email Formats
Connect Biopharma uses 1 email format. The most common is {first name}{last name} (e.g., johndoe@connectbiopharma.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@connectbiopharma.com | 100% |
Key Contacts at Connect Biopharma
Janies Garcia
Director Of It
Surendra Chaturvedi
Sr. Director, Head Of Quality And Regulatory Cmc
Jean Chen
风险与内控总监 Director Of Risk And Controls
Marissa Kinney
Associate Director Program Management
Barry Quart
Chief Executive Officer
Brandon Ngo
Senior Director Finance
Cindy J. Chen
Associate Director, Fp&A
Jelane Hart
Senior Director, Regulatory Affairs
Shawn Yang
Director Of Discovery Department
Company overview
| Headquarters | 3580 Carmel Mountain Road, Suite 200, San Diego, California 92130, US |
| Websites | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2012 |
| Employees | 21-50 |
| Socials |
About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target interleukin-4 receptor alpha (IL-4Rα). The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect also has an exclusive license and collaboration agreement for rademikibart with Simcere in China. Rademikibart is a fully human monoclonal antibody targeting IL-4Rα, a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the T helper 2 (Th2) inflammatory pathway to achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma. For more information visit www.connectbiopharma.com. The inclusion of forward-looking statements herein, including words such as "believe", should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the U.S. Securities and Exchange Commission (the “SEC”). Further information regarding these and other risks is included under the heading “Risk Factors” in our annual and periodic reports filed with the SEC. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements, and undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Connect Biopharma has 24 employees across 9 departments.
Departments
Number of employees
Funding Data
Connect Biopharma has never raised funding before.
Frequently asked questions
4.8
40,000 users



